ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
64 191,54
2,07%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Annovis Bio Inc (ANVS)

  7. Annovis Bio Inc (ANVS) Actualités

ANVS

Annovis Bio (ANVS)

Annovis Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:ANVS
DateHeureSourceTitreSymboleSociété
29/04/202416h10GlobeNewswire Inc.Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s DiseaseNYSE:ANVSAnnovis Bio Inc
02/04/202413h30GlobeNewswire Inc.Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:ANVSAnnovis Bio Inc
28/02/202413h08IH Market NewsUS Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters…NYSE:ANVSAnnovis Bio Inc
12/02/202420h00Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NYSE:ANVSAnnovis Bio Inc
01/02/202422h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:ANVSAnnovis Bio Inc
22/11/202322h27Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:ANVSAnnovis Bio Inc
21/11/202320h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ANVSAnnovis Bio Inc
08/11/202322h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ANVSAnnovis Bio Inc
02/11/202312h30Business WireAnnovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s PatientsNYSE:ANVSAnnovis Bio Inc
01/11/202317h28Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANVSAnnovis Bio Inc
01/11/202317h24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ANVSAnnovis Bio Inc
31/10/202313h00Business WireAnnovis Bio Announces Pricing of $7.5 Million Public OfferingNYSE:ANVSAnnovis Bio Inc
30/10/202321h48Business WireAnnovis Bio Announces Launch of Proposed Public OfferingNYSE:ANVSAnnovis Bio Inc
30/10/202321h42Business WireAnnovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)NYSE:ANVSAnnovis Bio Inc
24/10/202315h13Business WireAnnovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease ConferenceNYSE:ANVSAnnovis Bio Inc
21/09/202315h35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNYSE:ANVSAnnovis Bio Inc
15/08/202313h20Business WireAnnovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNYSE:ANVSAnnovis Bio Inc
18/07/202314h18Business WireContinued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International ConferenceNYSE:ANVSAnnovis Bio Inc
27/06/202313h30Business WireAnnovis Bio Announces the Filing of a Groundbreaking PatentNYSE:ANVSAnnovis Bio Inc
20/06/202318h05Business WireAnnovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)NYSE:ANVSAnnovis Bio Inc
16/06/202322h19Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ANVSAnnovis Bio Inc
08/06/202313h30PR Newswire (US)Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record PaceNYSE:ANVSAnnovis Bio Inc
10/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NYSE:ANVSAnnovis Bio Inc
28/04/202314h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:ANVSAnnovis Bio Inc
26/04/202322h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ANVSAnnovis Bio Inc
25/04/202312h01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NYSE:ANVSAnnovis Bio Inc
06/01/202313h30PR Newswire (US)Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership TeamNYSE:ANVSAnnovis Bio Inc
08/11/202223h35PR Newswire (US)Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate UpdateNYSE:ANVSAnnovis Bio Inc
20/10/202213h30PR Newswire (US)Annovis Bio to Present at the 2022 ThinkEquity Investor ConferenceNYSE:ANVSAnnovis Bio Inc
11/10/202213h30PR Newswire (US)Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's DiseaseNYSE:ANVSAnnovis Bio Inc
 Showing the most relevant articles for your search:NYSE:ANVS

Dernières Valeurs Consultées

EU
GLE
Societe Generale
EU
BN
Danone
FTSE
UKX
FTSE 100
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
NASDAQ
MSFT
Microsoft
EU
VK
Vallourec
EU
AF
Air FranceKLM
SPI
SP500
S&P 500
EU
AI
Air Liquide
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés